The future of cancer screening after COVID-19 may be at home
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The coronavirus disease 2019 (COVID‐19; severe acute respiratory syndrome coronavirus 2; SARS‐CoV‐2) pandemic has triggered dramatic and rapid actions. With shelter‐in‐place policies implemented throughout the United States, and patients fearful of exposure to COVID‐19 in health care facilities and physicians' offices, in‐office visits were no longer possible, and instead were replaced by video and telephone visits, as institutional support would allow. Professional societies such as the American Cancer Society issued recommendations that no one should go to a health care facility for routine (nondiagnostic) cancer screening until further notification.1 Other national professional societies issued similar recommendations (the American Society of Clinical Oncology, American Society of Breast Surgeons, American College of Radiology, and American Society for Colposcopy and Cervical Pathology) to postpone regular cancer screening until health care facilities resumed preventive visits.2-4 Prior to the pandemic, population screening rates for breast, cervical, and colorectal cancers among age‐eligible adults at average risk were rising, reaching parity among diverse population subgroups, although still not meeting the Healthy People 2020 goals.5-7 During the pandemic, analyses of national cancer screening patterns8 as of April 25, 2020, revealed a precipitous drop in cervical cytology and breast cancer screening of 94% each and of 86% for colorectal cancer screening.
Cancer , article en libre accès, 2019